CBL and the related CBL-B protein are two members of a family of RING ®nger type ubiquitin E3 ligases that are believed to function as negative regulators of signal transduction in hematopoietic and immune cells. In mice, expression of v-Cbl causes lymphomas, and targeted disruption of either the CBL gene or the CBL-B gene can result in a lymphoproliferative disorder or hypersensitivity of lymphocytes. CBL is one of the most prominent targets of the BCR/ABL tyrosine kinase oncogene. We compared the role of CBL and CBL-B in signal transduction of BCR/ABL using pairs of cell lines before and after expression of BCR/ABL. In contrast to CBL, BCR/ABL was found to rapidly downregulate the expression of CBL-B protein. The decrease in CBL-B protein induced by BCR/ABL was associated with downregulation of CBL-B mRNA. Downregulation and tyrosine phosphorylation of CBL-B required BCR/ABL kinase activity. However, despite their known similarities in structure and function, we found CBL and CBL-B proteins to be involved in distinct signaling complexes. CBL was predominantly in a complex with phosphatidylinositol 3'-kinase and CRKL, while CBL-B was not associated with any signi®cant phosphatidylinositol 3'-kinase activity. A major CBL-B associated protein was identi®ed as mono-ubiquitinated Vav, a nucleotide exchange factor for Rac1. These results demonstrate that BCR/ABL signals dierentially through CBL and CBL-B, with downregulation of the CBL-B protein potentially contributing to BCR/ABL-mediated transformation.
Introduction
The BCR/ABL oncogene has elevated tyrosine kinase activity that is crucial for transformation, although the actual mechanism of transformation is largely unknown. While many BCR/ABL tyrosine kinase substrates have been identi®ed, the exact function and contribution of these proteins to leukemia has yet to be elucidated. BCR/ABL signaling intermediates are likely to contribute to transformation by activating pathways that in¯uence cell growth, viability, adhesion, or other cellular processes. The intermediate signaling events that directly lead to transformation by BCR/ABL are not well understood and are of great interest in this ®eld. BCR/ABL is localized to the cytoskeleton and phosphorylates multiple substrates on tyrosine residues, including cytoskeletal proteins, cytoplasmic proteins, growth factor receptors, kinases, BCR/ABL itself and other proteins . Also, the direct interaction of BCR/ABL with two adaptor proteins, GRB2 and CRKL, has been shown to independently contribute to transformation. GRB2 binds to tyrosine 177 in BCR and thus links BCR/ABL to SOS and to RAS (Afar et al., 1994; Pendergast et al., 1993; Puil et al., 1994) . Similarly, CRKL binds to a proline rich domain in ABL and we and others have previously shown that CRKL thereby links BCR/ABL to the protooncogene CBL and PI3K (phosphatidylinositol 3'-kinase) (Sattler et al., 1996; Senechal et al., 1996) .
CBL (for Casitas B-lineage lymphoma) is one of the most prominently tyrosine phosphorylated proteins in BCR/ABL transformed cells (Andoniou et al., 1994) . Disruption of the CBL gene in mice leads to a hematopoietic phenotype that includes lymphoid hyperplasia and primary splenic extramedullary hematopoiesis. Also, CD3 stimulation of CBL (7/7) thymocytes induces hyperphosphorylation of cellular proteins, suggesting an important role in the regulation of lymphocyte activation for CBL (Murphy et al., 1998; Naramura et al., 1998) . When CBL is truncated to remove 60% of the C-terminus, as in v-cbl, the protein can transform B lymphocytes and ®broblasts (Mushinski et al., 1994) . v-cbl is the oncogene in a naturally occurring retrovirus that causes pre-B cell lymphomas and some myelogenous leukemias in mice (Fredrickson et al., 1984) . An internal 17 amino acid deletion of CBL (after amino acid 358) detected in the pre-B cell line 70Z/3 also activates the tumorigenic potential of this protein and is associated with increased tyrosine phosphorylation (Andoniou et al., 1994) .
The family of CBL proteins also includes CBL-B and CBL-3 (Keane et al., 1995 (Keane et al., , 1999 . CBL-B has been shown to have 50% protein sequence similarity with CBL, and both proteins have been identi®ed as potential E3 ubiquitin ligases (Fang et al., 2001; Joazeiro et al., 1999; Keane et al., 1995) . CBL-B contains all the known functional domains found in CBL, including a RING ®nger domain, a proline rich domain, a leucine zipper, a nuclear localization signal, and several tyrosine residues that are potential targets for kinases. It is ubiquitously expressed, although its protein level, in contrast to that of CBL, appears to be upregulated during myeloid dierentiation (Keane et al., 1995) . The role of CBL-B as a negative regulator of lymphocyte activation has been well described. Mice with Cbl-B gene disruption are characterized by in®ltration of activated lymphocytes in multiple organs and spontaneous autoimmunity (Chiang et al., 2000; Krawczyk et al., 2000) . CBL-B also inhibits epidermal growth factor receptor function by inducing ubiquitination and down regulation (Ettenberg et al., 1999a,b) . Although the signaling functions of CBL-B are not well characterized, it can interact with several SH3 containing proteins that have previously been shown to bind to CBL, such as GRB2 and PI3K (Fang et al., 2001; Keane et al., 1995; Sattler et al., 1996) . Overexpression of neither CBL-B nor CBL can induce transformation (Ettenberg et al., 1999a; Hamilton et al., 2001; Mushinski et al., 1994) .
In this study, we have compared BCR/ABLmediated signaling through CBL and CBL-B. We show that expression of the CBL-B gene is directly regulated by BCR/ABL, while expression of CBL is unchanged. Further, CBL and CBL-B coprecipitate with dierent complexes of tyrosine phosphorylated proteins. In contrast to CBL, CBL-B does not bind to a signi®cant amount of CRKL in BCR/ABL transformed cells, and the coprecipitation of PI3K protein and lipid kinase activity is small. Nevertheless, both proteins were found to bind to the BCR/ABL oncoprotein. CBL-B was found to be associated with a major 105 kDa ubiquitinated band that contained a small amount of VAV. Inhibitors of proteasome activity increased the ubiquitination of VAV but not the protein levels. The signi®cant downregulation of CBL-B may have a dierent role in transformation by BCR/ABL than CBL.
Results

CBL-B protein is downregulated in cells transformed by oncogenic tyrosine kinases
CBL is a prominent target of tyrosine kinases and is likely to be involved in the regulation of PI3K in BCR/ ABL transformed cells. CBL family members are of special interest in BCR/ABL signaling since they are thought to be negative regulators of lymphocyte activation (Chiang et al., 2000; Krawczyk et al., 2000; Murphy et al., 1998; Naramura et al., 1998) . We sought to compare the signaling properties of CBL and the related protein CBL-B in BCR/ABL transformed cells. Surprisingly, CBL-B immunoprecipitations indicated that CBL-B protein levels were reduced in MO7e.p210 cells (37% decrease) compared to untransformed MO7e cells, while the ABL kinase inhibitor STI571 led to upregulation (60% increase) of CBL-B in MO7e.p210 cells (Figure 1, top panel) . CBL-B expression could also be reinduced by STI571 treatment of the Philadelphia chromosome positive cell lines BV173 and K562 (75 and 107% increase respectively) but did not alter CBL-B expression in the BCR/ABL negative B cell lymphoma cell line Blin-1 (Figure 1, top panel) . This demonstrates that ABL kinase activity is required for the downregulation of CBL-B.
We next compared the re-expression of CBL-B protein by STI571 to SHIP1, an inositol polyphosphate 5'-phosphatase that we previously found to be downregulated by BCR/ABL . Within 2 h, STI571 led to reexpression of both CBL-B and SHIP1 in Ba/F3.p210 cells but protein levels were not maximal until 8 h of STI571 treatment (Figure 1 
BCR/ABL regulates expression levels of CBL-B mRNA in MO7e cells
In an attempt to determine if the CBL-B levels are regulated by a change in mRNA we analysed CBL-B levels by real-time PCR. The STAT5 regulated gene PIM-1 was used as a control gene. Consistent with the above data, real-time PCR analysis demonstrated that inhibition of the BCR/ABL kinase activity in the Ph+cell line K562 with the ABL kinase inhibitor STI571 increased CBL-B expression (2.6-fold change) and decreased PIM-1 (77.1-fold change) expression (Figure 2a , top panel). STI571 did not have a signi®cant eect on either CBL-B or PIM-1 expression levels in the B-cell line Blin-1, which is transformed by a mechanism independent of BCR/ABL. As a control for the speci®city of the PCR reaction, we con®rmed the expected size of the PCR products by polyacrylamide gel analysis. There was no signi®cant ampli®ca-tion of a PCR product through primer dimerization in the absence of cDNA template (Figure 2a , bottom panel), and we did not ®nd any signi®cant contamination by genomic DNA in the PCR reaction (not shown). In particular, using isolated RNA as a template and the PCR primers for b-actin or ribosomal protein S9, we determined that there was insigni®cant ampli®cation with a 2610 6 -fold reduced abundance compared to the reaction in the presence of cDNA.
We had previously demonstrated that multiple BCR/ ABL signaling pathways can also be activated through an increase in intracellular ROS (reactive oxygen species). ROS can mimic some aspects of transformation, such as increased cellular tyrosine phosphorylation, inhibition of protein tyrosine phosphatase activity, altered migration or cell cycle progression (Sattler et al., 1999b (Sattler et al., , 2000 . We found that BCR/ABL and oxidative stress induced by H 2 O 2 (Figure 2b ), but not growth factor stimulation by granulocyte-macrophage colony stimulating factor (not shown), regulated CBL-B levels. BCR/ABL induced downregulation of CBL-B (72.4-fold change) and upregulation of PIM-1 (4.6-fold change) in MO7e.p210 cells, compared to untransformed MO7e cells (Figure 2b , right panels). Downregulation of CBL-B (72.7-fold change) and upregulation of PIM-1 (3.2-fold change) was also found by H 2 O 2 treatment of MO7e cells (Figure 2b , left panels). Surprisingly, treatment of MO7e cells with H 2 O 2 led only to a slight reduction in CBL-B protein levels (not shown). The change in mRNA was found to be time-dependent and maximal within 6 h of treatment.
CBL-B associates with VAV in BCR/ABL transformed cells
CBL-B contains a RING ®nger domain and has previously been shown to act as ubiquitin E3 ligase for p85PI3K in T-cells (Fang et al., 2001) . In BCR/ ABL transformed Ba/F3 cells, we did not observe any signi®cant coprecipitation of p85PI3K with CBL-B or ubiquitination of p85PI3K, even when CBL-B was reexpressed at levels comparable to untransformed cells (not shown). To determine if CBL-B coprecipitates with ubiquitinated proteins or is ubiquitinated itself, Ba/F3 and Ba/F3.p210 cells were either left untreated or treated for 18 h with the proteasome inhibitor ALLN (Figure 3a , top panel). In BCR/ABL transformed Ba/F3 cells, but not untransformed cells, CBL-B was found to coprecipitate with a 105 kDa ubiquitinated protein but not to be ubiquitinated itself ( Figure 3a , bottom panel). The ubiquitination of this protein was changed in Ba/F3.p210 cells, suggesting that it is a target for ubiquitination in BCR/ABL transformed cells. Treatment with the proteasome inhibitor ALLN resulted in a modest increase in the association of the ubiquitinated protein with CBL-B.
To further determine if CBL-B protein expression is regulated in part by degradation, we re-expressed a hemagglutinin (HA)-tagged version of CBL-B in Ba/F3.p210 cells. As reported previously, there are alternatively spliced forms of CBL-B that would account for a doublet (Keane et al., 1995) and the HA-tagged expression construct gives rise to the smaller of the two forms. CBL-B was found to be re-expressed at levels comparable to Ba/F3 cells ( Figure 3b ). Anti-HA immunoblotting indicated that only a very small amount of CBL-B was degraded into smaller, faster migrating forms. In addition, proteasome inhibitors including ALLN, MG132, and lactacystin, as well as lysosome inhibitors, including leupeptin and ammonium chloride, did not signi®cantly alter CBL-B levels in BCR/ABL transformed cells (not shown).
Even though CBL-B may act as a ubiquitin E3 ligase for p85PI3K in T-cells (Fang et al., 2001 ), we did not detect any signi®cant coprecipitation or ubiquitination of PI3K with CBL-B, even when CBL-B was reexpressed to levels comparable to those seen in untransformed cells (not shown). In contrast, the nucleotide exchange factor VAV was found to be part of the 105 kDa ubiquitinated band that coprecipitated with CBL-B in BCR/ABL transformed cells ( Figure  3c ). Treatment of Ba/F3.p210 cells with MG132 increased cellular ubiquitination and the amount of the ubiquitinated band coprecipitating with CBL-B. The amount of VAV coprecipitating with CBL-B was found to be small compared to the cellular pool of VAV. Only a small amount of the 97 kDa protein VAV was ubiquitinated in BCR/ABL transformed Ba/F3 cells and migrated as a 105 kDa monoubiquitinated band (not shown). MG132 treatment modestly increased the association of CBL-B with the ubiquitinated form of VAV (Figure 3c , bottom panels). The size of the ubiquitinated species suggests that VAV is only mono-ubiquitinated and therefore not necessarily targeted for degradation through the proteasome pathway (Hicke, 2001) . Consistent with these ®ndings, MG132 does not increase protein levels of VAV in BCR/ABL transformed cells (not shown).
CBL-B interacts with BCR/ABL but not PI3K or CRKL in transformed cells
Re-expression of CBL-B to levels similar to parental Ba/F3 cell line did not decrease growth rates of Ba/F3.p210 cells (not shown). BCR/ABL may signal through multiple redundant pathways for growth. To determine if CBL-B has a role comparable to CBL in signaling, we looked for tyrosine phosphorylation of CBL-B and its potential association with proteins that are known to bind to CBL. We have previously shown that the BCR/ABL oncogene induces tyrosine phosphorylation of CBL and formation of a complex containing BCR/ABL, CBL, CRKL, and PI3K (Sattler et al., 1996) . CBL-B immunoprecipitations demonstrate that the protein is tyrosine phosphorylated in Ba/F3.p210 cells but not in Ba/F3 cells and associates with tyrosine phosphorylated proteins with apparent molecular masses of 210, 140, 90, 72, and 65 ± 50 kDa ( Figure 4a, top panel) . In contrast to CBL, no coprecipitation of tyrosine phosphorylated proteins with a molecular mass between 40 kDa and 50 kDa was seen. The 210 kDa protein in CBL-B immunoprecipitates of BCR/ABL transformed cells was identi®ed as BCR/ABL by anti-ABL immunoblotting. We did not detect any coprecipitation of CRKL with CBL-B (not shown) and coprecipitation of the 85 kDa subunit of PI3K was minimal (Figure 4a, bottom panel) . In addition, the interaction of both CBL and CBL-B with BCR/ABL was signi®cantly reduced by pretreatment of Ba/F3.p210 cells with the ABL kinase inhibitor STI571, suggesting that the tyrosine phosphorylation of either protein is important for interaction (data not shown).
Next, the association of CBL-B and CBL with CRKL, PI3K, and BCR/ABL in immunoprecipitates was investigated. CRKL, PI3K and BCR/ABL are tyrosine phosphorylated in Ba/F3.p210 cells and immunoprecipitate with a 120 kDa tyrosine phos- To con®rm the above data, we measured the PI3K activity in CBL and CBL-B immunoprecipitates from unstimulated Ba/F3 and Ba/F3.p210 cells. As a control, PI3K activity was measured in anti-phosphotyrosine immunoprecipitates. A small and potentially insigni®cant amount of PI3K activity was found to be associated with CBL, CBL-B and anti-phosphotyrosine immunoprecipitates of Ba/F3 cells (Figure 4c) . A signi®cant increase in PI3K activity was detected in anti-phosphotyrosine and CBL immunoprecipitates of BCR/ABL transfected Ba/F3 cells. In contrast, BCR/ ABL did not increase the amount of PI3K activity associated with CBL-B. These results demonstrate that BCR/ABL increases the association of active PI3K with CBL but not CBL-B.
BCR/ABL has previously been shown to induce tyrosine phosphorylation of CBL (Andoniou et al., 1994) . Using GST-fusion proteins of CBL (amino acid 589 ± 712, human sequence) and CBL-B (amino acid 600 ± 721, human sequence) as substrates for the BCR/ ABL kinase in immunoprecipitations, no in vitro kinase activity towards these fusion proteins was detected (not shown). In contrast, BCR/ABL was found to readily phosphorylate a GST-CRKL fusion protein in vitro in this assay. The CBL fusion protein contained a tyrosine residue (amino acid 700) which was previously shown to be the major tyrosine phosphorylated residue in BCR/ABL transformed cells (Andoniou et al., 1996) and the CBL-B peptide contained two Tyr-X-X-Pro motifs (Y 665 -X-X-P, Y 709 -X-X-P) which are predicted to be good candidates for phosphorylation by the BCR/ABL kinase.
CBL-B regulates spontaneous transwell migration in BCR/ABL transformed Ba/F3 cells
BCR/ABL transformed Ba/F3 cells demonstrate a signi®cant level of spontaneous migration. Using the doxycycline inducible expression system, we cotransfected BCR/ABL and CBL-B expression vectors and selected for hygromycin resistant cells in the presence of IL-3. CBL-B levels were increased several fold after doxycycline treatment in transfected cells ( Figure 5 , top panel). The eect on transwell migration of CBL-B transfected cells was investigated after doxycycline treatment and compared to untreated cells. We had previously shown that doxycycline treatment alone does not alter transwell migration (Sattler et al., 1999a) . The migration index of 0.84 (n=3, P50.02) in cells expressing CBL-B demonstrates a signi®cant decrease in spontaneous migration ( Figure 5 , bottom panel). In contrast, control treatment of Ba/F3.p210 cells induced no decrease in transwell migration and the mean of the migration indices was found to be 1.07 (n=3, P=0.22). These data suggest that CBL-B is likely to be involved in BCR/ABL induced spontaneous migration. In similar experiments, we did not observe a signi®cant eect of CBL-B on cell survival or cell growth in this cell system.
Discussion
Although many BCR/ABL tyrosine kinase substrates have been identi®ed, the exact function and contribution of these proteins to leukemia has yet to be elucidated. BCR/ABL signaling intermediates are likely to contribute to transformation by activating pathways that in¯uence cell growth, viability, adhesion, or others . In an attempt to determine the potential role of the RING type ubiquitin E3 ligase CBL and CBL-B in BCR/ABL induced transformation, we found that expression of CBL-B was down- . We found that, in addition to protein levels, CBL-B mRNA levels were also reduced. The small amount of CBL-B protein remaining was heavily tyrosine phosphorylated in BCR/ABL transformed cells.
It is not known what the exact downstream targets of CBL-B are, but it is likely that it functions in part through ubiquitination of target proteins (Fang et al., 2001) . To understand the potential signi®cance of the downregulation of CBL-B, we investigated the possibility of protein ubiquitination and degradation of CBL-B itself as well as associated proteins. Overexpression of a HA-tagged form of CBL-B indicated that there was only a very small and likely insigni®cant amount of smaller degraded forms of HA-tagged CBL-B present in BCR/ABL transformed cells. In addition, treatment of cells with inhibitors of proteases and lysosome or proteasome function did not alter protein levels of CBL-B, suggesting that regulation of CBL-B expression is mainly due to a decrease in its mRNA levels. Interestingly, inhibition of the proteasome pathway increased association of CBL-B with a major ubiquitinated protein but CBL-B was not ubiquitinated itself. CBL-B had been previously described to be a ubiquitin E3 ligase for p85PI3K (Fang et al., 2001 ), but PI3K was not found to be signi®cantly ubiquitinated or associated with CBL-B. We identi®ed the ubiquitinated CBL-B-associated protein as VAV. Even though VAV is ubiquitinated in BCR/ABL transformed cells, protein levels did not signi®cantly change. The size of the ubiquitinated band was consistent with monoubiquitination, which may not necessarily target the protein for degradation (Hicke, 2001) .
In contrast to CBL-B, CBL protein was not found to be signi®cantly downregulated by BCR/ABL. Also, the proteins detected in a complex with CBL and CBL-B were dierent. In particular, there was BCR/ABLdependent association of PI3K with CBL, but not CBL-B, and there was no evidence that CBL-B bound to CRKL. CBL-B contains a proline rich motif (PPPPLRDPPPPPP at amino acid 546 ± 559) that could be a potential site for binding of the PI3K SH3 domain (Rickles et al., 1994) . Our previous data suggest that the interaction of CBL with the SH3 domain of the p85 subunit of PI3K is not sucient for formation of a stable complex, and that it is only after tyrosine phosphorylation that CBL can recruit PI3K into a stable complex (Sattler et al., 1996) . In work not shown, we also could not detect any association of CBL-B with PI3K in cells re-expressing CBL-B at levels comparable to untransformed cells. It is therefore likely that BCR/ABL does not induce tyrosine phosphorylation of a tyrosine in CBL-B that would be a suitable site for the p85PI3K SH2 domain. CBL has two potential p85 SH2 docking sites (Tyr371 and Tyr731). However, only Tyr731 serves as a p85 SH2 interaction site . CBL-B has a conserved Tyr364 that is likely to be homologous to the non-utilized CBL site but it has no other conserved p85 docking sites in the C-terminus. CBL may be involved in the regulation of PI3K activity, which in turn has been shown to be required for transformation by BCR/ABL (Skorski et al., 1995) . PI3K downstream signaling events in BCR/ABL transformed cells include activation of the serine-threonine kinase AKT (Skorski et al., 1997) . AKT kinase has been demonstrated to be involved in anti-apoptotic signaling by phosphorylating BAD, a member of the BCL-2 family (Datta et al., 1997; Delpeso et al., 1997) . Despite this apparent importance of PI3K signaling, the mechanism of PI3K activation in BCR/ABL transformed cells has been dicult to identify. Therefore, the data presented here suggest that CBL-B has dierent signaling properties than CBL. It is possible that CBL-B competes for binding with some CBL binding partners, but fails to bind others such as PI3K and CRKL.
CBL-B has several tyrosine residues that are potential targets for tyrosine kinases. In an attempt to identify the CBL-B kinase, we were unable to demonstrate that BCR/ABL itself has this function in vitro, although BCR/ABL coprecipitates with CBL-B. Although CBL-B and CBL share binding partners such as BCR/ABL, it is uncertain from our ®ndings if CBL and CBL-B compete for binding to BCR/ABL, but this is a possibility since the proteins do not apparently coprecipitate despite their common interaction with the oncoprotein. The lack of interaction of CBL and CBL-B has also previously been shown (Ettenberg et al., 1999a) . CBL can homodimerize through the UBA/LZ domain and the inability of CBL and CBL-B to coimmunoprecipitate therefore suggests that they do not heterodimerize (Bartkiewicz et al., 1999) . CBL has been found to bind and to be a substrate of other tyrosine kinases such as LYN and FYN (Donovan et al., 1994; Fukazawa et al., 1995; Tanaka et al., 1995; Tezuka et al., 1996) and this may also be a reasonable mechanism for tyrosine phosphorylation of CBL-B in BCR/ABL transformed cells. The role of tyrosine kinases in the regulation of CBL-B expression and function is apparent since inhibition of the BCR/ABL tyrosine kinase activity in transformed cells leads to upregulation of CBL-B.
There is little known about the regulation of gene expression by BCR/ABL in transformed cells. BCR/ ABL-induced downregulation of CBL-B could contribute signi®cantly to transformation. In vivo, downregulation of CBL-B by targeted disruption of the gene in mice has been shown to lead to hyperresponsiveness of lymphocytes with in®ltration of activated T-cells and B-cells into multiple organs, and parenchymal damage. For example, activation of the T-cell receptor led to enhanced VAV function (Chiang et al., 2000; Krawczyk et al., 2000) . VAV is a Rac1 nucleotide exchange factor that has been shown before to interact directly with CBL-B (Bustelo et al., 1997) . Transformation of hematopoietic cells by BCR/ABL requires activation of Rac1, likely through a PI3K-dependent mechanism (Skorski et al., 1998) . VAV may also be involved in the regulation of c-Jun N-terminal kinase stimulation (Bustelo et al., 1997) . Downregulation of CBL-B in transformed cells is also to some degree consistent with previous ®ndings demonstrating an increase of CBL-B in HL60 and U937 cells, which were induced to dierentiate in vitro (Keane et al., 1995) . In contrast, epidermal growth factor receptor ligation leads to CBL-B ubiquitination and a decrease in CBL-B through protein degradation (Ettenberg et al., 2001) . Nevertheless, our data suggest that BCR/ABL regulates the expression of multiple genes and the combined regulation is likely to contribute to transformation.
One of the most interesting signaling pathways regulated by BCR/ABL includes the induction of ROS (Sattler et al., 2000) . The potential role of ROS in transformation has been shown by overexpression of the superoxide-generating NADPH oxidase Mox1 in NIH3T3 ®broblasts, which increases cell growth and induces tumors in athymic mice (Suh et al., 1999) . On the other hand, inhibition of superoxide dismutase (SOD), an enzyme that catalyzes the reduction of superoxide to H 2 O 2 , by the estrogen derivative 2-methoxy-estradiol kills leukemia cells, but not normal lymphocytes (Huang et al., 2000) . This suggests that ROS levels in hematopoietic cells are regulated to maintain a ®ne balance between ROSsupported cell survival and free-radical-mediated cell death. It is possible that altered ROS levels in BCR/ ABL transformed cells contribute to a change in CBL-B levels. However, our data do not indicate if BCR/ABL regulates CBL-B mRNA levels directly, through a mechanism that involves ROS, or another BCR/ABL-dependent mechanism. Additional studies will be necessary to determine the exact mechanism of CBL-B mRNA regulation by BCR/ABL and ROS.
BCR/ABL induces multiple cytoskeletal abnormalities that aect motility, morphology and adhesion . It has been suggested that altered cytoskeletal function leads to premature release of CML cells from the marrow, accumulation of myeloid cells in the blood and thus may contribute to the leukemic phenotype in CML (Gordon et al., 1987; Verfaillie et al., 1992) . Downregulation of CBL-B by BCR/ABL and increased cell migration may therefore contribute to an increased release of cells from the bone marrow. This could be in synergism with other proteins such as SHIP, which we have also previously shown to regulate BCR/ABL mediated migration (Sattler et al., 1999a) .
Overall, one model consistent with our data would be that the BCR/ABL oncoprotein alters mRNA levels of CBL-B and other genes. These signals could include the reduction in activity of one or more PTPases. BCR/ABL also induces tyrosine phosphorylation of CBL and CBL-B, but the oncoprotein forms distinct complexes that include either CBL or CBL-B but not both concomitantly. It is not clear at this time if CBL and CBL-B are involved in related signaling pathways or if they regulate each other's function. It is likely that further elucidation of the functions of the CBL and CBL-B complexes will be helpful in understanding the signaling pathways of these related proteins, especially as they relate to VAV.
Materials and methods
Cell culture
The murine pre-B cell line Ba/F3 or cell line transfected with a kinase dead BCR/ABL cDNA (Ba/F3.p190-k.d.) and the human megakaryocytic cell line MO7e were grown in the presence of IL-3 and GM-CSF, respectively, and maintained as described (Sattler et al., 2000) . Cell lines transfected with a BCR/ABL cDNA (Ba/F3.p210 or Ba/F3.p190 and MO7e.p210), a TEL/ABL cDNA (Ba/F3.TEL/ABL), a TEL/JAK2 cDNA (Ba/F3.TEL/JAK2), and a TEL/PDGFR cDNA (Ba/F3.TEL/PDGFR) were grown in the absence of growth factors. The Philadelphia chromosome positive cell line K562 and the human T cell line Blin-1 were grown in RPMI 1640 containing 10% fetal calf serum. For stimulation studies, Ba/F3 or MO7e cells were deprived of growth factors for 18 h at 378C in serum free medium containing 0.5 or 1% (w/v) bovine serum albumin, respectively.
Stimulation of cells and preparation of cellular lysates
MO7e and Ba/F3 were left untreated or stimulated for the indicated times with H 2 O 2 in RPMI 1640 at a concentration of 5610 6 cells/ml. Cells were washed in cold PBS and cell lysates were prepared as described .
Expression constructs and transfection
A human CBL-B cDNA (with N-terminal HA tag) was subcloned into the pCEFL expression vector under the control of the human elongation factor-1 promoter. The vectors were used for transfection into Ba/F3 cells by electroporation (Gene Pulser, Bio-Rad, Hercules, CA, USA) and the cells were harvested after 30 h. In addition, the CBL-B cDNA was subcloned into the pTRE2 expression vector (Clontech Laboratories, Palo Alto, CA, USA). Ba/F3 cells stably transfected with a plasmid containing the reverse tetracycline-controlled transactivator (Ton.BaF.1, obtained from GQ Daley, MIT, Cambridge, MA, USA) were used for transfection and cultured under the same conditions as the Ba/F3 cell line. To generate stable cell lines, pTRE2-CBL-B expression constructs were cotransfected with a BCR/ABL expression construct containing a hygromycin resistance gene into Ton.BaF.1 cells. Hygromycin resistant clones were selected in the presence of IL-3, and CBL-B expression was induced by treatment with 1 mg/ml doxycycline for 24 h in the absence of IL-3.
Immunoprecipitation and immunoblotting
Immunoprecipitation and immunoblotting using a chemiluminescence technique were performed as described (Sattler et al., 2001) . Immunochemical detection of tyrosine phosphorylated proteins in Western blots utilized monoclonal antibody 4G10 (kindly provided by Dr B Druker, Oregon Health Science University, Portland, OR, USA). Polyclonal rabbit antisera were obtained against CBL (Santa Cruz Biotech, Santa Cruz, CA, USA), CRKL (Santa Cruz Biotech), and the p85 subunit of PI3K (Upstate Biotechnology Inc, Lake Placid, NY, USA), and polyclonal goat antisera were obtained against CBL-B (Santa Cruz Biotech). Monoclonal antibodies were obtained against ABL (Calbiochem, Cambridge, MA, USA) and ubiquitin (Santa Cruz Biotech). Murine monoclonal antibodies against the N-terminal SH3 domain of CRKL (Uemura et al., 1997) and the SH2 domain of ABL (clone 5H11) and VAV (Upstate Biotechnology, Lake Placid, NY, USA) were used for immunoblotting in this study. In some experiments, the change in CBL-B levels was quanti®ed using the NIH Image analysis program by Wayne Rasband at the National Institute of Health (NIH).
Primers for polymerase chain reaction
Gene speci®c primers (Biosource, Camarillo, CA, USA) were designed from sequences in the GenBank TM data base using the Primer Express 1.5 software (Applied Biosystems). The actin gene and the ribosomal protein S9 gene were used as endogenous control to standardize the amount of RNA in each reaction. Gene speci®c primers: CBL-B (forward: 5'-CGGTAATTGTTGCGTTTCCA-3'; reverse: 5'-ACAGCTC-GCTCCCGAAGAA-3'), pim-1 (forward: 5'-TGCGGCACT-GCCACAA-3'; reverse: 5'-CGCGATTGAGGTCGATAA-GG-3'), ribosomal protein S9 (forward: 5'-CCGCGTGAA-GAGGAAGAATG-3'; reverse: 5'-TTGGCAGGAAAAC-GAGACAAT-3'), and actin (forward: 5'-TTGCCGACA-GGATGCAGAA-3'; reverse: 5'-GCCGATCCACACGGAG-TACT-3'). The size of the amplicon was con®rmed by polyacrylamide gel electrophoresis and SYBR gold (Molecular Probes, Eugene, OR, USA) staining.
Real-time polymerase chain reaction
RNA was isolated by the Trizol TM method (Gibco) from starved, H 2 O 2 -stimulated (150 mM) and BCR/ABL transformed MO7e cells or Blin-1 and K562 cells that were either left untreated or treated for 18 h with 1 mM STI571 (Gleevec; Novartis Pharmaceuticals, Basel, Switzerland). cDNA was generated (Advantage RT-for-PCR kit, Clontech) from 1 mg of total RNA and the formation of PCR products monitored using the SYBR green method (PCR master mix, Applied Biosystems). PCR was performed on the cDNA samples using an ABI PRISM 7700 sequence detector (PE Applied Biosystems), and all samples were ampli®ed in triplicate. The relative change in amount of transcripts in each sample was determined by normalizing for actin and S9 mRNA expression levels, as described previously (ABI PRISM sequence detection system user bulletin No. 2, PE Applied Biosystems).
Phosphatidylinositol 3'-kinase enzyme assay
The in vitro activity of phosphatidylinositol 3'-kinase was measured in anti-ABL, CBL, and CBL-B immunoprecipitates of unstimulated Ba/F3 and Ba/F3.p210 cell lysates. The kinase assay was performed as described (Prasad et al., 1993a,b) .
Transwell migration assay
The lower chamber of a transwell plate (8 mm pore size polycarbonate membrane, Corning Costar Corp, Cambridge, MA, USA) was ®lled with 600 ml media (10% (v/v) FCS in RPMI 1640). Cells were counted using a Coulter particle counter (Coulter Counter Z2, Beckman Coulter, Fullerton, CA, USA) and resuspended at 2610 6 cells/ml in media. One hundred ml of this cell suspension was transferred to the upper chamber. The medium contained either doxycycline (1 mg/ml) or no stimulus in the control samples. After 2.5 h, cells in the lower compartment were resuspended and counted using a Coulter particle counter. The spontaneous transwell migration of cells was expressed as a`migration index' (number of migrating cells treated with doxycycline divided by the number of migrating cells left untreated). The standard error of the mean was calculated from the migration indices of independently performed experiments. The statistical signi®cance of the data was analysed using the Student's t-test.
